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Abstract We measured the minimum inhibitory concentration (MIC) of the antimi-
crobial peptide pexiganan acting on Escherichia coli, and report an intrinsic vari-
ability in such measurements. These results led to a detailed study of the effect of
pexiganan on the growth curve of E. coli, using a plate reader and manual plating
(i.e. time-kill curves). The measured growth curves, together with single-cell obser-
vations and peptide depletion assays, suggested that addition of a sub-MIC concen-
tration of pexiganan to a population of this bacterium killed a fraction of the cells,
reducing peptide activity during the process, while leaving the remaining cells unaf-
fected. This pharmacodynamic hypothesis suggests a considerable inoculum effect,
which we quantified. Our results cast doubt on the use of the MIC as ‘a measure of
the concentration needed for peptide action’ and show how ‘coarse-grained’ studies
at the population level give vital information for the correct planning and interpre-
tation of MIC measurements.
Keywords: antimicrobial peptide; pexiganan; Escherichia coli; minimum inhibitory
concentration; killing curves; inoculum effect
1 Introduction
The discovery of the β -lactam antibiotic penicillin by Fleming in 1928 was a mile-
stone of 20th-century medicine. Today, the rampant spread of antimicrobial re-
sistance (AMR) constitutes a grand challenge facing medical science in the new
century (Aminov, 2010), which, if not met, will turn a ‘strep throat’ back into a
life threatening illness. To confront AMR, more effective ways of using of exist-
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ing agents, including dosing regimes less prone to generating AMR, are urgently
needed, as are new agents. In either case, standardised measures of effectiveness
allowing science-based comparison between different agents are clearly required.
In the global effort to confront AMR, antimicrobial peptides (AMPs) have at-
tracted considerable attention (Fjell et al, 2012). These short peptides (≈ 10 to 50
residues) are widely distributed among metazoans, with diverse sequence and struc-
ture. Certain motifs recur, e.g. high net positive charge under physiological condi-
tions, and/or α-helical conformation in solution or upon binding to membranes; but
these motifs are not universal. AMPs are effective against a wide spectrum of bac-
teria, viruses and fungi in natura. The hope is that some natural or synthetic AMPs
may be suitable therapeutic antimicrobial agents, especially against AMR strains.
The 23-residue AMP magainin-2 secreted by the African clawed frog Xenopus
laevis and its ‘relatives’ have attracted particular attention. Pexiganan (or MSI-78),
a synthetic 22-residue magainin analogue (Gottler and Ramamoorthy, 2009), was
trialed for topical treatment of diabetic foot ulcers, but was denied approval in 1999
because it seemed no more effective than antibiotics already in use for such ulcers
(Moore, 2003); however, future clinical approval remains a possibility (Gottler and
Ramamoorthy, 2009). Partly due to on-going efforts to secure such approval, pexi-
ganan has been well studied.
A large biophysical literature exists on AMPs in general, and pexiganan in par-
ticular, focussing on the molecular modus operandi. Partly as a result of substantial
research into how pexiganan and similar AMPs interact with lipid bilayers in unil-
amellar vesicles (Gottler and Ramamoorthy, 2009), it is widely believed that this
and other α-helical AMPs lyse bacteria by membrane poration.
We consider the other end of the length scale spectrum, and report a study of
the modus operandi of pexiganan on E. coli at the population level. Such ‘coarse-
grained’ studies using rather classical methods (albeit in updated, high-throughput,
forms) are seldom performed today. Our results show how such work is needed to
complement molecular-level studies, preventing the misinterpretation of pharmaco-
dynamic measurements performed to judge the concentration required for antimi-
crobial action against live bacteria.
We start by measuring the minimum inhibitory concentration (MIC), which is
the most important ‘one-number characterisation’ of the effectiveness of an antimi-
crobial agent against a target organism. Loosely, it is the minimum concentration of
an antimicrobial agent necessary to cause stasis (no growth). We re-determine the
MIC of pexiganan on E. coli, but using more repeat experiments than has ever been
reported before. A critique of using MIC to characterise potency based on our mea-
surements leads us to study the effect of pexiganan on the growth curve of E. coli,
which turns out to be strikingly different from the way many classical antibiotics
change the growth curve of the same bacterium.
Our growth curves, along with single-cell observations, peptide depletion assays
and time-kill curves, suggest that adding sub-MIC concentrations of this AMP to a
population of E. coli rapidly kills a fraction of the cells, leaving the rest to grow un-
affected while at the same time removing active AMP molecules from the medium.
As Udekwu et al (2009) have previously suggested, the depletion or deactivation
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of an antibiotic causes an ‘inoculum effect’ (dependence of MIC on initial inocu-
lum concentration), which we quantify for pexiganan. We end by discussing the
implications of our findings on the interpretation of the MIC in mechanistic and
pharmacodynamic contexts.
2 Materials and methods
2.1 Bacteria culture
We worked with E. coli K-12 derived strain MG1655 (Blattner et al, 1997). Five
colonies, grown on an Mueller Hinton Broth (MHB) agar plate, were touched with a
sterile loop and introduced to a 5 ml MHB liquid culture, which were grown at 37◦C
and 200rpm to OD=0.5 (600nm). We also grew bacteria in the filtered supernatant of
cells lysed by sonication. Ten 30 second pulses of sonication applied to 10ml of E.
coli culture resting on ice achieved a 99.98% reduction in viability. The supernatant
was filtered (0.22µm) to remove the surviving cells.
2.2 Pexiganan
Pexiganan (GIGKFLKKAKKFGKAFVKILKK-NH2) was synthesised on a Liberty
microwave peptide synthesizer (CEM Corporation) using standard solid phase Fmoc
protocols on Rink amide-MBHA resins with HCTU/DIPEA as coupling reagents.
Peptides were purified by semi-preparative RP-HPLC on a JASCO HPLC system
(model PU-980, Tokyo, Japan) and confirmed by MALDI-ToF mass spectrometry
(Bruker Daltonics Ltd, UK) with α-cyano-4-hydroxycinnamic acid as the matrix.
We prepared stock solutions at 2mM in sterile, distilled water, which were stored
at −20◦C and defrosted immediately before using and refreezing.
2.3 Growth curves and MIC
We followed a published protocol for MIC determination using microdilution assays
in microtiter plates (Wiegand et al, 2008) that is consistent with the guidelines of
the Clinical and Laboratory Standards Institute and the European Committee on An-
timicrobial Susceptibility testing. MIC assays were prepared in 96-well polystyrene
microtiter plates (Greiner) with 200µl cylindrical wells. Initial inoculum sizes of
n0 = 5×105 cell/ml were incubated in and their optical density read (at 600nm) by a
FLUOstar Optima (BMG Labtech) plate reader with lid-covered plates that allowed
air flow. We checked that our MIC results were the same using either polystyrene
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or polypropylene plates. Note that we report pexiganan concentrations in µM to
facilitate comparison with cell concentrations in cells/ml, where 0.4µM = 1µg/ml
(using the molecular weight of 2477gmol−1). Literature values in µg/ml have been
converted to and quoted in µM.
2.4 Single-cell imaging
To determine times to first division, we took time-lapsed phase-contrast images
of cells using a Nikon TE300 Eclipse inverted microscope with a 100× PH3 oil-
immersion objective and a CoolSNAP HG2 CCD camera (Photometrics). MHB
agar pads were set into adhesive Gene Frames (Thermo Scientific). Pexiganan at
3µM was added to E. coli at OD=0.5 and the solution was left to incubate for 3
minutes before pipetting 1µl onto the agar pad. The E. coli were spread by tipping
the microscope slide and within ∼ 4.5 minutes all liquid had, by eye, disappeared.
We then mounted a glass coverslip to the gene frame in contact with the agar pad.
The sample was immediately transferred to the microscope, pre-heated to 37◦C in a
temperature-controlled box, for observation.
2.5 Time-kill curves
We grew E. coli MG1655 following the same protocol as for MIC assays and di-
luted to 5×105 cell/ml. We worked with 3ml of suspension in two tubes (Greiner,
polystyrene, 50ml). Pexiganan was added to one of these at time t = 0 min and both
incubated at 37 ◦C and shaken at 200 rpm. A 100µl sample was removed from both
tubes 1min after peptide addition, a range of ten-fold dilutions were spread onto
MHB agar plates in triplicate. No more than 5 samples were removed, resulting in a
17% volume reduction, which is somewhat above the recommended maximum re-
duction in standard protocols. The agar plates were incubated at 30 ◦C for 16h before
the colonies were counted manually and density of cells calculated in cell-forming
units (CFU) per ml.
2.6 Pharmacodynamic studies
We followed literature procedures (Udekwu et al, 2009) to determine the effect of
residual AMP. Two tubes containing 5ml of MHB and 40µM of pexiganan were
prepared, one of which was inoculated with 5×106 cells/ml. After 18 h incubation
both suspensions were filtered and the supernatant used to set up two MIC assays in
a 96 well plate each, alongside two replicate control MIC assays using the standard
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1 2 3 4 5 6 7 8 9 10 11 12
A MHB MHB MHB MHB MHB MHB MHB MHB MHB MHB MHB MHB
B 10 10 10 10 10 10 10 10 10 10 10 10
C 5 5 5 5 5 5 5 5 5 5 5 5
D 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5
E 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25
F 0.63 0.63 0.63 0.63 0.63 0.63 0.63 0.63 0.63 0.63 0.63 0.63
G 0.31 0.31 0.31 0.31 0.31 0.31 0.31 0.31 0.31 0.31 0.31 0.31
H 0 0 0 0 0 0 0 0 0 0 0 0
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Fig. 1 (a) Data from one dilution experiment in a 96-well plate. Numbers are pexiganan concen-
trations in µM in the 200µl wells, each inoculated with n0 = 5×105 cells/ml. MHB = buffer with
no cells. Each column is one dilution series. Yellow = wells with an OD ≈ 10× the OD of MHB
wells after 24h. (b) Fraction of wells that showed apparent bacterial growth for 20 replicates as a
function of pexiganan concentration, with the zero pexiganan point plotted on the left end of the
logarithmic horizontal axis.
protocol. A further two assays were set up with supernatant from the tube which had
contained both cells and peptide, with 20µM of freshly-added pexiganan.
3 Minimum inhibitory concentration
Figure 1(a) shows representative raw data for our determination of the MIC of pex-
iganan for E. coli MG1655 using microdilution assays in microtiter plates, with
growth after 24h detected by a plate reader.1 In our 96-well plate, each of the 12
columns constitutes a separate MIC determination. Thus, e.g., in column 4 of the
plate shown, the minimum concentrating showing no growth at 24h is 5µM, which
therefore by definition is the MIC from this particular dilution series. In these 12
replicates, then, five return a MIC of 2.5µM (columns 1, 2, 8, 9 and 11), four re-
turn a MIC of 5µM (columns 4, 6, 7 and 12), and three columns (3, 5 and 10)
show a seemingly ‘impossible’ pattern of ‘re-entrant growth’: after being inhibited
at 2.5µM, growth apparently restarted at 5µM.2
What, then, is the MIC of pexiganan acting on E. coli MG1655? Our data, Fig-
ure 1(a), do not allow us to assign a unique value, but if such a value exists, then it
lies in the region of 2.5 to 5µM. Previous studies have returned values in the range
of 3.2 to 12.8µM against various isolates (Fuchs et al, 1998; Ge et al, 1999), placing
our range of 2.5µM to 5µM at the low end of the spectrum.3
1 See http://datashare.is.ed.ac.uk/handle/10283/1885 to access relevant data
on which this article is based.
2 Continuing the experiment to 72h did not change the observed growth/no-growth pattern.
3 This is perhaps unsurprising given that MG1655 is a laboratory strain that has been described as
‘deceitful delinquents growing old disgracefully’ (Hobman et al, 2007).
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However, to compare our results and previous work in terms of a range of values
masks a fundamental qualitative difference between our work and almost all previ-
ous MIC measurements. We, like the majority of the literature, follow best-practice
guidelines (Wiegand et al, 2008; CLSI, 2012). The difference is that we perform
multiple (12) replicates of the same MIC assay on a single plate. This is almost
never done in the literature. Instead, commercial ‘MIC plates’ are used with wells
pre-loaded to give single dilution series of multiple antimicrobial agents. Alterna-
tively, the same dilution series of a single agent is used to test multiple organisms,
again with one dilution series per organism.4 The range of literature values quoted
above for pexiganan acting on E. coli therefore arises from single-dilution-series
measurements on many isolates, whereas our own range of values arises from vari-
ability between multiple replicates on a single strain, Figure 1(a).
When a single dilution series is used, as is the case in the majority literature,
the issue of disagreement between replicates does not arise. On the rare occasion
where two replicates are prepared and they disagree, such as our columns 7 and
8 (Figure 1), the disagreement is typically ascribed to ‘dilution error’. Literature
protocols do occasionally mention ‘re-entrant growth’, but would ascribe this to ac-
cidental ‘skip’ or to ‘single well contamination’. In particular, if we follow Hendrik-
sen (2010), we should identify our wells D3, D5, D10 as ‘skips’, and in these cases
take the ‘true MIC’ to be 10µM. 5 Repeated dilution error, skip or contamination at
the same point of our multiple dilution series seem highly improbable. Moreover,
repeated measurements showed similar patterns of variability seen in Figure 1(a), in-
cluding ‘reentrant growth’. Thus, the variability revealed by our results is intrinsic,
and reporting a single MIC is misleading. A better way to summarise our findings
is to plot the fraction of wells showing growth as a function of pexiganan concen-
tration. Figure 1(b) shows such a plot for the 12 replicates shown in Figure 1(a) and
another 8 replicates performed using the same peptide stock and inoculum.
Intrinsic variability is consistent with a previous meta-study (Annis and Craig,
2005), which ascribed half of the variability uncovered in a survey of literature
values of the MICs of various antibiotics against E. coli and Staphylococcus aureus
to laboratory-to-laboratory differences. Presumably, then, it is possible that at least
part of the other half of the variability is attributable to intrinsic causes, although
Annis and Craig attributed this ‘commonly shown 3-fold dilution range’ entirely to
environmental factors such as temperature, inoculum size and incubation time.
To begin to elucidate the source of the MIC variability, we turn to consider the
full growth curves that were collected and used to generate the MIC data.
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Fig. 2 Sub-MIC growth curves for E. coli with an initial inoculum size of n0 = 5×105 cells/ml at
the same pexiganan concentrations used for the 96-well plate experiment in Figure 1 and stated in
the legend. (a) Raw OD data against time. (b) The same data with OD at t = 0 subtracted. (c) Log-
linear plot of the data in (b). (d) The time to reach OD = 0.12, τ0.12, plotted against concentration
of pexiganan. In parts (b) and (c), OD = 10.12 is shown as dashed lines.
4 Sub-MIC growth curves
Figure 2(a) shows a typical set of growth curves of E. coli MG1655 at sub-MIC con-
centrations of pexiganan (background subtracted in Figure 2(b) and (c)), from the
MIC assays displayed in Figure 1(a). While such curves are collected in every mi-
crotiter assay, they are seldom, if ever, presented or interpreted. Exceptions concern
the response of E. coli to tetracycline and amoxicillin (Schuurmans et al, 2009) and
to cefotaxime (Baraban et al, 2011). At sub-MIC concentrations tetracycline and ce-
fotaxime reduce the population growth rate and stationary level whilst amoxicillin
does not significantly affect the growth curves until the MIC is reached.
Pexiganan does not influence the maximum growth rate (measured to be α =
0.034± 0.01min−1) or the stationary level of the population (a background sub-
tracted OD of ≈ 2.5), but lengthens the time until growth is detected6 in a con-
centration dependent manner. Figure 2(c) plots the time taken to measure an OD
4 E.g., no replicats are suggested in the guidelines for loading a 96-well plate for testing a range of
agents on E. coli and Salmonella isolates in a WHO project (Hendriksen, 2010).
5 See Figure 2 in Hendriksen (2010). If, alternatively, we identify our wells C3, C5 and C10,
Figure 1, as contaminated, then the ‘true MIC’ would be taken to be 2.5µM.
6 We detected growth in a well at 2× 107 cells/ml, similar to what was reported previously for
multi-well plate readers (Pin and Baranyi, 2006; Me´tris et al, 2006). Lengthened detection times
due to peptide action recalls the ‘virtual colony count’ (VCC) approach developed to measure
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of 0.12 above the OD of MHB (τ0.12), which increases with pexiganan concentra-
tion. Note that without pexiganan, the population takes 160±10 min to grow to OD
= 0.12 = 1± 0.4× 108 cell/ml. An initial inoculum of 5× 105 cells/ml will reach
1×108 cell/ml in α−1 ln(2×102) = 156min with our measured α . The population
lag time is therefore immeasurably small.
The variation in τ0.12 between wells increases with pexiganan concentration. In
particular, the large differences in τ0.12 between replicates at 2.5µM correlates well
with the observation, Figure 1, that some wells do not show growth within 24 h at
this concentration. No replicate experiments were reported in previous growth curve
studies. In the case of cefotaxime (Baraban et al, 2011), the smooth variation of
growth curves at closely-spaced antibiotic concentrations allows us to conclude that
there should be little variation between replicates. We therefore infer an intriguing
difference vis-a`-vis stocasticity between pexiganan and cefotaxime. We cannot draw
a similar conclusion from data for tetracycline and amoxicillin (Schuurmans et al,
2009) because only a few concentrations were studied.
5 Single cell observations
Next, we probe the cause of the observed effect of pexiganan concentration on τ0.12,
the growth curve detection time. There are two generic ways in which the peptide
could affect cells at early times to increase τ0.12. Either some of the initial inoculum
dies, and the remaining cells take longer to grow to a given density even if their
growth rate remains unaltered, or growth of all the cells is retarded, giving the same
macroscopic observed effect on τ0.12. To observe directly the early-time effect of
sub-MIC concentrations of pexiganan, we imaged cells spread on agar and recorded
the time to first division (TTFD) of each cell, thought to be the sum of the lag time
and first generation time (Rasch et al, 2007; Me´tris et al, 2005). We chose conditions
(caption, Figure 3) that resulted in sufficient cell death to demonstrate the effect of
pexiganan, whilst leaving enough live cells to collect meaningful data.
The TTFD distribution for the pexiganan-free control, Figure 3 (red), is spread
over ∼ 50min due to heterogeneities in growth stages, single-cell lag times7 and
generation times. On exposure to 3µM of pexiganan for 3 min before being placed
on the agar, a fraction of the cells never go on to divide. Some are clearly dead
(showing less contrast and do not grow) by the time the first image was taken, but
others grow initially and then stop at later times. Some cells lyse suddenly whilst
other fade over time. Interestingly, 29% of the cells which grow and divide give
rise to a daughter cell that subsequently dies. Importantly, the TTFD distribution of
cells that survive and divide to form colonies does not seem to differ greatly to that
defensin activity (Ericksen et al, 2005). However, unlike in VCC, bacteria in our case were exposed
to peptides in their growth medium rather than grown in a peptide-free medium after exposure.
7 Cells with the shortest single cell lag times dominate the population lag (Baranyi, 1998), which
can be crudely calculated to be ∼ 10 min after the transfer procedure from liquid culture to agar.
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Fig. 3 Normalised histogram of times to first division for E. coli on agar. Unexposed to pexiganan
(red) and exposed to 3µM pexiganan for 3 min (black) Inset shows the same plot if the time to
second division is counted for all first divisions resulting in the death of a daughter cell.
of the control sample, Figure 3 (black and red respectively). Including cells whose
daughters subsequently die shifts the distribution only slightly (inset).
These data suggest that exposure to pexiganan results either in death or leaves the
cells unaffected to go on to grow and divide, at least for cells inoculated onto agar.
A number of caveats are, however, in order. First, the concentration of peptides the
cells are exposed to is uncontrolled while the inoculum drop is evaporating after be-
ing placed on the agar surface. Thereafter, the peptides are be free to diffuse into the
agar away from the cells. It is therefore possible that under more prolonged expo-
sure than is possible under our experimental conditions, e.g., in liquid medium, the
growth of surviving cells would be retarded. Nevertheless, our experiments certainly
show that the main effect of pexiganan is to kill a proportion of the cells rapidly.
6 Depletion of active peptide
It is important to know whether this rapid initial killing of cells significantly affects
the concentration of free peptides. Towards this end, we first determine if the peptide
is depleted with time in our assays we performed the MIC experiments detailed in
section 2.6. MIC assays using pre-incubated peptide showed that the activity of the
peptide degrades by a factor of 2 to 4 times over 24 h in MHB at 37◦C, perhaps
due to peptide aggregation, common for magainins, or adhesion to components of
the medium. However, this is a small contribution to what was found when bacteria
had also been in the solution. An assay containing 40µM of pexiganan and 5×106
cell/ml, after being incubated and then filtered to remove any survivors, no longer
had any measurable affect on the growth of a new inoculum, so that (from Section 3)
we know that the pexiganan concentration must be below 2.5µM. In other words, the
activity of the peptide was reduced more than 16-fold. When an additional 20µM of
peptide was added to this solution and serially diluted with MHB it resulted in a MIC
10 Jepson et al.
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Fig. 4 Platecounted time-kill curves in MHB for pexiganan concentrations shown in the legend
for the inoculum size n0 = 5×105 cells/ml.
4× greater that that of a control. Not only had the original peptide been depleted but
the additional peptide showed less activity in this solution than in MHB. Similar
experiments conducted without filtering gave the same results, so that the filtering
was not responsible for removing active peptide molecules or complexes.
Following these findings, we used a suspension containing the filtered remains of
sonicated cells grown in MHB to prepare a MIC assay instead of MHB alone. Even
at the highest concentration of 20µM pexiganan, there was no measurable effect on
the inoculum of 5× 105 cell/ml, suggesting a reduction in the antimicrobial action
of the peptide of by 10 to 20 fold. It appears that the presence of lysed bacteria
reduces peptide activity. A plausible hypothesis is that positively-charged peptides
are depleted by adhesion to negatively-charged DNA and proteins, and/or by the
action of proteolytic enzymes from lysed cells.
7 Sub-MIC time-kill curves
If we are right that pexiganan kills a fraction of cells at short times upon addition,
our growth curves ought to show an initial decrease in numbers. This is not borne out
by our plate reader data, Figure 2. We now demonstrate that this is simply because of
lack of detection sensitivity. By using plate counts to measure the number of viable
E. coli as a function of time after the addition of pexiganan to their medium, i.e. by
determining time-kill curves (Section 2.5), it is possible to detect much lower cell
densities than is possible using a plate reader. We added pexiganan at t = 0min to
concentrations of 1, 2.5, 5 or 10µM and collected plate-count data for the first 200
min, and then once the following day.
Figure 4(a) shows time kill curves for an inoculum size of 5× 105 cell/ml, the
same as that used for MIC assays in the plate reader. As can be expected from
the results shown in Section 3, no viable cells were recorded at any time point at
10µM. At lower concentrations the density of viable cells in the suspension drops
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at early times; the higher the peptide concentration, the larger the drop in initial
viability. This is as expected from the only previous publication of pexiganan time-
kill curves (Ge et al, 1999). These measurements however were performed at above-
MIC concentrations, and only monitored for 120 minutes.
We measured at lower concentrations and for longer and therefore observe the
viability of E. coli increasing again at later times. The higher the peptide concen-
tration, the longer before recovery starts; however, after one day, all samples have
recovered to the same level.
Regrowth after an initial drop in viability has been reported in the time-kill curves
of other AMPs (Matsuzaki et al, 1998; McGrath et al, 2013; Spindler et al, 2011).
It has been attributed to ‘resistance’, with little evidence given in support. To verify
that no resistance had developed in our case, we exposed E. coli that had regrown in
our experiments to 2.5 and 5µM pexiganan, and found them as susceptible as cells
from the parent population.
Our results confirm that the lack of an initial phase of negative growth in our plate
reader data, Figure 2, is simply due to lack of detection sensitivity, and strengthens
the case for our suggestion that pexiganan kills a fraction of the cells at early times,
leaving the rest to grow unaffected. The literature has only recently suggested that
such non-monotonic time-kill curves can be due to a dynamic state of balanced divi-
sion and death rather than the historically assumed sub-population of non-dividing
persister cells (Wakamoto et al, 2013).
The killing of a fraction of cells in a clonal population leaving the rest of the
cells unaffected is striking. Given the large number of peptides per bacterium in the
system (∼ 109, much more than is needed to cover each cell in a monolayer however
the peptide is oriented) (Wimley, 2010), the observed heterogeneity is unlikely to be
due to fluctuations in the number of peptides strongly interacting with each cell. In-
stead, the heterogeneity most likely arises from phenotypic variations in a property
or properties of single cells. Our evidence shows that the survivors are not a sub-
population of non-dividing cells. Perhaps, then, cell surface heterogeneities, e.g. in
the structure of the lipopolysaccharides (Lerouge and Vanderleyden, 2002) or in the
expression of fimbrae (Abraham et al, 1985), are responsible for our observations.
Note that at peptide concentrations approaching the MIC, e.g., & 2.5µM for the
inoculum size relevant to Figure 4, the number of viable cells drops to rather low
levels (the minima at 2.5µM and 5µM in Figure 4 correspond to 2000 and 20 cells
per well respectively) before net growth begins. Such low numbers lead to large fluc-
tuations; in particular, some replicates could easily have all cells eradicated at these
peptide concentrations. This is the source of the observed fluctuations in Figure 1,
which make it difficult to determine ‘the MIC’ based on a single measurement.
8 The inoculum effect
If pexiganan kills a certain fraction of cells outright, depletes the number of active
peptides, and leaves the remaining cells to grow, then there should be a strong in-
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oculum effect (IE): the MIC should be higher for higher inoculum densities. The
IE is important because the in vitro population density of pathogens could be sig-
nificantly higher than typical inocula cell densities in MIC assays. The magnitude
of the IE for a small number of inocula concentrations is reported in the antimicro-
bial literature (Udekwu et al, 2009), including for some AMPs (Levison et al, 1993;
Jones et al, 1994); but possible causative mechanisms have seldom been discussed,
partly because data for MICs over a large range of inocula densities are, with very
few exceptions (Udekwu et al, 2009), not reported.
We report such data for pexiganan acting on E. coli. Figure 5(a) shows the frac-
tion of growing wells against pexiganan concentration for four different inoculum
sizes, n0 = 2.5×107, 5×105 (our standard inoculum size), 5×103 and 5 cell/ml.8
Qualitatively, these data are similar to those shown in Figure 2. Quantitatively, the
pexiganan concentration at which the fraction of growing wells drops to zero, which
we take in this context to be the MIC, increases with inoculum size, n0. Figure 5(b)
plots this MIC as a function of n0 from two sets of results: one which collates data
from multiple assays done over a long period of time, and a second set where the
data were collected in one experiment using the same peptide stock for each inocu-
lum size. In both cases, the MIC approaches a constant value at low n0, and increases
sub-linearly at higher n0 (the dashed line in Figure 5(b) has unit slope).
Perhaps the simplest way to account for an inoculum effect, given our observa-
tion of depletion of active peptides by cell lysis, is that each lysed cell inactivates a
fixed number of antimicrobial molecules. However, in its simplest form, this mech-
anism should lead to a linear dependence of the MIC on n0 at high enough n0. It
is possible that our observed sub-linear n0 dependence is en route to such a linear
dependence, but we do not reach high enough inoculum concentrations to observe
it. On the other hand, a speculative explanation for a sub-linear dependence at all
n0 is that cells aggregate at high densities and high peptide concentrations,9 which
may (Moiset et al, 2013) allow peptide molecules or complexes to affect two cells
simultaneously.
9 Discussion: What really is the MIC?
The overwhelming majority of existing MIC measurements rely on a single series of
dilution assays performed at one inoculum size (typically 5×105 cells/ml) to deter-
mine a one-off concentration of antimicrobial agent at which no growth is observed
after 24 hours. This ‘one-off MIC’ is frequently assumed to represent, in the words
of Melo et al (2009), ‘the macroscopically observable threshold for the onset of
[antimicrobial] activity’. This implies that sub-MIC concentrations of antimicrobial
agents are sub-lethal towards the target cells. In the light of our findings, both the
8 Note that 5 cells/ml ≡ 1 cell/well, so that the fraction of growing wells is < 1 at zero pexiganan.
9 We have seen such aggregation in optical microscopy (data not show).
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Fig. 5 (a) Fraction of growing wells as a function of pexiganan concentration, for inocula of n0 =
2.5× 107 (blue), n0 = 5× 105 (black), n0 = 5× 103 (green) and n0 = 5 cells/ml(≡ 1cell/well)
(red). (b) The MIC, defined as the concentration of pexiganan at which no replicate grows, plotted
agains inoculum size, n0, for one set of experiments using the same pexiganan stock (grey) and
data collated from many tests (black). The dashed line has unit slope.
practice of determining a ‘one-off MIC’ value and the quoted interpretation of the
significance of this value are problematic, at least for pexiganan acting on E. coli.
First, we have found, using multiple replicates, that the ‘one-off MIC’ shows
large intrinsic variability, Figure 1(a). This is because at these peptide concentra-
tions, cell numbers drop very low before net regrowth starts, Figure 4, and such
low numbers give rise to significant stocasticity. Instead of a ‘one-off MIC’ from a
single dilution series, findings from multiple replicates, reported as the fraction of
samples in which no growth is observed after 24 hours as a function of the peptide
concentration, Figure 1(b), are necessary to give adequate information.
Secondly, we have shown that exposure to sub-MIC levels of pexiganan kills a
fraction of E. coli in a population quickly, leaving the remaining cells to grow at a
rate that is indistinguishable from that of cells never exposed to the AMP, Figure 3.
Indeed, the MIC for a standard inoculum size (5× 105 cell/ml) is ∼ 10× above
its single-cell action threshold: compare the black and red data sets in Figure 5(a).
Thus, it is not true that the MIC of pexiganan is ‘the macroscopically observable
threshold for the onset of [antimicrobial] activity’. Instead, if a single value is de-
sired to quantify the ‘single-cell action threshold’ of pexiganan on E. coli MG1655,
a reasonable candidate is the concentration for the onset of lengthening detection
times, τ0.12: compare Figure 2(d) with the red curve in Figure 5(a).
The interpretation that the MIC itself is a ‘single-cell action threshold’ clearly lies
behind a substantial body of literature. Thus, e.g., Ramamoorthy et al (2006) found
a MIC of 4µM for pexiganan acting on E. coli using an inoculum of 107 cell/ml,
but observed outer membrane perturbation (according to an ANS uptake assay) at
the significantly lower concentrations of 0.67µM after only 5 minutes of incubation.
Ramamoorthy et al (2006) infer that factors other than membrane disruption must be
involved in the bacterial killing process. A later study came to a similar conclusion
on similar grounds (Pius et al, 2012). Our findings mean that this inference is neither
necessary nor likely correct: a fraction of cells should be killed (presumably by
mechanisms involving membrane perturbation) at 0.67µM. 0.2×MIC. In general,
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then, understanding what MIC values mean is crucial if pharmacodynamic results
are to be correctly compared with mechanistic studies.
Thirdly, there is strong evidence that peptides causing cell death are sequestered
and unavailable for further bactericidal action. This finding should influence the
way in which comparative data between different AMPs are interpreted. Thus, e.g.,
Fluorogainin-1 is designed to be a ‘more stable’ analogue of pexiganan. It displays
a lower MIC against S. aureus (Gottler et al, 2008). Our findings suggest that this
could be because Fluorogainin-1 is not depleted as rapidly. Separately, one could
postulate that mutant strains more resistant to pexiganan (Perron et al, 2006) could
have evolved more efficient mechanisms for peptide inactivation in lysed cells, thus
raising the measured MIC. These scenarios are speculative, but illustrate once more
the need to consider carefully the meaning of MIC measurements.
Finally, we have quantified the inoculum effect (IE) of pexiganan acting on E.
coli, Figure 5(b). There is no IE for n0 . 103 cells/ml; thereafter, MIC ∝ nα0 with
α ≈ 0.4. This finding has significant practical and theoretical implications.
Practically, while the IE is well known, it is seldom quantified. In lieu of quan-
tification, it is presumably natural to assume that the MIC is essentially proportional
to n0, especially if the antimicrobial agent is known to be depleted by the process
of killing bacteria. Making this assumption in the case of pexiganan acting on E.
coli MG1655 would lead to very substantial errors, with knock-on implication for
dosage regimes arising from pharmacokinetic studies based on such an assumption.
Theoretically, we note that our power law with α ≈ 0.4 also fits the data for 5 out
of the 6 antibiotics for which the IE has been quantified (Udekwu et al, 2009) (we
find α between 0.3 and 0.5 fitting their data to power laws). Intriguingly, Udekwu
et al (2009) found no depletion of the antibiotic for 3 of these 5 antibiotics. It is a
challenge for future theoretical modelling to decide whether a deeper generic mech-
anism underly such similarity, or whether two or more mechanisms fortuitously lead
to similar quantitative IEs.
Overall, we suggest that data like those presented in Figure 5(a) should form the
minimum basis for interpreting MIC measurements in the context of mechanistic
studies, pharmacodynamic modelling, and clinical decision making for all antimi-
crobial agents. More specifically, given that many bactericidal AMPs are structurally
similar to pexiganan, we surmise that our findings concerning the modus operandi of
pexiganan, e.g., that its action is likely crucially linked to phenotypic heterogeneity
of the target organism, may generalise to other compounds. For example, prelim-
inary data on the MIC of amhelin, a pore-forming peptide designed by Rakowska
et al (2013), shows the same growth curve (Figure 2) and IE (Figure 5(b)) as pexi-
ganan. Future research should explore the validity of this surmise for a wider range
of AMPs, especially those that, like pexiganan, are bactericidal.
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